CGON
Cg Oncology Inc
NASDAQ · Biotechnology
$50.36
+1.16 (+2.36%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.47M | 3.06M | 1.55B | 1.61B | 1.48B |
| Net Income | -113,634,452 | -213,464,844 | -216,062,695 | -285,460,132 | -250,904,762 |
| EPS | — | — | — | — | — |
| Profit Margin | -7,729.5% | -7,343.0% | -13.9% | -17.7% | -17.0% |
| Rev Growth | -52.1% | -52.1% | +6.3% | +15.2% | +12.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.50B | 1.65B | 1.56B |
| Total Equity | — | — | 2.54B | 2.51B | 2.29B |
| D/E Ratio | — | — | 0.59 | 0.66 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -147,957,913 | -293,383,463 | -300,127,009 | -344,556,820 | -320,224,465 |
| Free Cash Flow | — | — | -249,842,018 | -296,727,069 | -277,168,820 |